NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $52.51 -1.17 (-2.18%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$51.81▼$54.8250-Day Range$41.68▼$53.6852-Week Range$27.02▼$73.00Volume402,859 shsAverage Volume374,117 shsMarket Capitalization$1.89 billionP/E RatioN/ADividend YieldN/APrice Target$92.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Keros Therapeutics alerts: Email Address Keros Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.5% Upside$92.17 Price TargetShort InterestBearish9.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 4 Articles This WeekInsider TradingSelling Shares$11 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.78) to ($5.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector562nd out of 910 stocksPharmaceutical Preparations Industry259th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingKeros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKeros Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Keros Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.67% of the outstanding shares of Keros Therapeutics have been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Keros Therapeutics has recently increased by 10.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KROS. Previous Next 1.9 News and Social Media Coverage News SentimentKeros Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Keros Therapeutics this week, compared to 2 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,002,500.00 in company stock.Percentage Held by Insiders22.90% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($4.78) to ($5.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -10.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Keros Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About Keros Therapeutics Stock (NASDAQ:KROS)Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More KROS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KROS Stock News HeadlinesAugust 16, 2024 | insidertrades.comKeros Therapeutics, Inc. (NASDAQ:KROS) Director Carl L. Gordon Sells 250,000 SharesSeptember 5 at 9:58 AM | markets.businessinsider.comKeros Therapeutics (KROS) Receives a Buy from Truist FinancialSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankSeptember 4 at 5:15 AM | markets.businessinsider.comKeros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS TrialAugust 28, 2024 | globenewswire.comKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesAugust 9, 2024 | markets.businessinsider.comStrong Financials and Promising Clinical Trials Bolster Buy Rating for Keros TherapeuticsAugust 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics as KER-065 Shows Promise in Obesity and Neuromuscular DisordersAugust 7, 2024 | globenewswire.comKeros Therapeutics Reports Second Quarter 2024 Financial ResultsSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 1, 2024 | finance.yahoo.comKeros Therapeutics, Inc. (KROS)June 25, 2024 | benzinga.comAnalyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech GrowthJune 17, 2024 | globenewswire.comKeros Therapeutics Announces Leadership UpdatesJune 17, 2024 | globenewswire.comKeros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationJune 10, 2024 | seekingalpha.comKeros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood CancersMay 28, 2024 | globenewswire.comKeros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsMay 21, 2024 | investing.comKeros Therapeutics Inc (KROS)May 14, 2024 | globenewswire.comKeros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationMay 10, 2024 | finance.yahoo.comKeros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical TrialsSee More Headlines Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KROS CUSIPN/A CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$92.17 High Stock Price Target$105.00 Low Stock Price Target$60.00 Potential Upside/Downside+75.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,990,000.00 Net Margins-62,012.55% Pretax Margin-62,012.55% Return on Equity-44.73% Return on Assets-41.06% Debt Debt-to-Equity RatioN/A Current Ratio20.37 Quick Ratio20.37 Sales & Book Value Annual Sales$271,000.00 Price / Sales6,991.77 Cash FlowN/A Price / Cash FlowN/A Book Value$11.22 per share Price / Book4.68Miscellaneous Outstanding Shares36,084,000Free Float27,821,000Market Cap$1.89 billion OptionableOptionable Beta1.22 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jasbir S. Seehra Ph.D. (Age 68)President, CEO & Director Comp: $1.13MMr. Keith C. Regnante MBA (Age 54)Chief Financial Officer Comp: $636.11kMr. Christopher Rovaldi M.Sc. (Age 49)Chief Operating Officer Comp: $784.9kMs. Esther Cho J.D.Senior VP, General Counsel & SecretaryMs. Robin WagnerSenior Vice President of Human ResourcesMr. John Oram M.B.A.Senior Vice President of Program & Portfolio ManagementMore ExecutivesKey CompetitorsSierra OncologyNASDAQ:SRRAScholar RockNASDAQ:SRRKY-mAbs TherapeuticsNASDAQ:YMABDicerna PharmaceuticalsNASDAQ:DRNAAmarinNASDAQ:AMRNView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 84,810 shares on 8/20/2024Ownership: 1.050%Point72 Asset Management L.P.Sold 601,531 shares on 8/19/2024Ownership: 1.026%Algert Global LLCBought 1,505 shares on 8/16/2024Ownership: 0.044%The Manufacturers Life Insurance Company Bought 2,517 shares on 8/15/2024Ownership: 0.047%Point72 Asia Singapore Pte. Ltd.Bought 2,811 shares on 8/15/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $39.76 on January 1st, 2024. Since then, KROS stock has increased by 32.1% and is now trading at $52.51. View the best growth stocks for 2024 here. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by $0.02. The business had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative trailing twelve-month return on equity of 44.73%. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $75 million in an initial public offering on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Keros Therapeutics' top institutional investors include Darwin Global Management Ltd. (4.23%), Candriam S.C.A. (1.22%), Nantahala Capital Management LLC (1.05%) and Point72 Asset Management L.P. (1.03%). Insiders that own company stock include Jennifer Lachey, Christopher Rovaldi, Keith Regnante and Julius Knowles. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA) and Karyopharm Therapeutics (KPTI). This page (NASDAQ:KROS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
